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development of a successful medical insti-
tution. His story puts the individual struggle
against cancer into a larger context, celebrat-
ing the courage of survivors, medical pro-
fessionals, and scientists throughout history.
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As the development of drugs continues
to advance in the new decade, the develop-
ment of molecular biomarkers must likewise
advance in order to ensure that patients con-
tinue to receive the best possible standard of
care. In Molecular Pathology in Drug Dis-
covery and Development, editor J. Suso
Platero argues that future medical care will
need to be tailored to individual patients. In
ordertofacilitatethispersonalizedmedicine,
Platero states that clinicians and researchers
ought to work together to produce biomark-
ers and therapeutic agents simultaneously,
thereby streamlining our ability to under-
standdiseasepathology,finddrugtargets,se-
lectpatientslikelytobenefitfromadrug,and
determine the efficacy of new drugs.
Themajorityofthebookfocusesonhow
molecular biomarkers have been utilized in
cancertreatment,althoughtheauthorsdooc-
casionally touch on other diseases such as
HIV/AIDS and cystic fibrosis.Arguably, the
work might be improved by a more in-depth
discussion of the latter diseases, since the
overwhelmingfocusoncancerleadstoacer-
tain level of redundancy between the chap-
ters. On the other hand, it must be
acknowledged that the authors’ depiction of
the historical development of cancer bio-
markersiswelldone.Oneofthecentralideas
put forth over the course of the book is that
clinicians and researchers should always be
open to the development of new biomarkers,
rather than preselecting a set of biomarkers
for a given drug. The authors discuss how
clinical trials may be conducted in order to
discover and incorporate novel biomarkers,
therebyimprovingourunderstandingofboth
disease pathology and treatment feasibility.
MolecularPathologyinDrugDiscovery
and Development also contains a plethora of
technical information on how biomarkers
should be measured and interpreted.The au-
thors discuss thebestways to generatetissue
slides and harvest nucleic acids for analysis.
Various pathological techniques are dis-
cussed, with special emphasis placed on im-
munohistochemistry (IHC), transcriptional
profiling,andautomotivequantitativeanaly-
sis (AQUA). Detailed explanations of how
biomarkers should be analyzed also are pro-
vided, and colored inserts offer readersvalu-
able examplesof how histologicalslides and
microarray results may appear.
What may be the main criticism of the
book is that the authors prefer to discuss in-
stances in which biomarkers already have
been proven to be useful rather than hypoth-
esizing on how biomarkers may evolve in
the future. Although the authors do give a
brief overview of how AQUA may provide
better measurement of biomarkers than IHC,
the majority of the information discussed is
of a technical nature. It seems as though the
work might have benefitted from either an
extended discussion of recently developed
assays or an analysis of how our current use
of biomarkers might be improved. Such a
discussion would give readers an idea of
how they could to contribute to the field.
Overall, Molecular Pathology in Drug
Discovery and Development is a well-writ-
ten book that provides both an overview of
how biomarkers may be developed and de-
tailed explanations of how to measure and
analyze said biomarkers. Although the na-
ture of the book’s subject matter may make
it more useful to clinicians and scientists in-
terested in treating cancer, its in-depth ex-
planations of various assays make it useful
to anyone interested in molecular pathology.
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